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Purpose: HIV-infected patients are at increased risk for cardiovascular disease, 
which may be mediated in part by inflammation. This study aimed to evaluate the 
risk factors of carotid plaque, and clinical factors associated with carotid athero-
sclerosis measured by carotid intima-medial thickness (cIMT) in HIV patients. 
Materials and Methods: Clinical and cardiometabolic factors as well as cIMT 
were prospectively measured in 145 HIV-infected participants who had received 
combined antiretroviral therapy for ≥6 months. The mean value of the bilateral av-
erage cIMT level was used as Mean-IMT in the analysis, and the greatest value 
among the measured cIMT levels was used as Max-IMT. Results: Among 145 pa-
tients, 34 (23.4%) had carotid plaque. Multivariate logistic regression analysis re-
vealed three independent risk factors of carotid plaque: old age [odds ratio (OR) 
6.16, 95% confidence interval (CI) 1.09-34.88; p=0.040], hypertension (OR 12.62, 
95% CI 1.72-92.49; p=0.013) and higher low-density lipoprotein cholesterol 
(LDL-C) (OR 1.08, 95% CI 1.01-1.16; p=0.039). Levels of estimated glomerular 
filtration rate were inversely associated with Mean-IMT (r=-0.379, p<0.001) and 
Max-IMT (r=-0.389, p<0.001). Stepwise multivariate regression analyses revealed 
that age, total cholesterol and fasting glucose were positively correlated with 
cIMT, independent of other risk factors. Conclusion: The presence of hyperten-
sion, old age and a higher level of LDL-C were independent risk factors of carotid 
plaque among HIV-infected subjects.
Key Words:   Carotid plaque, carotid artery intima-media thickness, atherosclero-
sis, combined antiretroviral therapy, HIV infection
INTRODUCTION
Combined antiretroviral therapy (cART) plays a critical role in suppressing viral 
titers and increasing CD4+ T lymphocyte counts, which translate to significantly 
reduced morbidity and mortality in HIV-infected individuals.1,2 However, it now 
appears clear that both HIV infection itself and cART are associated with a higher 
risk of stroke and metabolic disorders.3,4 In a cross-sectional study of 292 sub-
jects, a CD4+ T-cell count less than 100 cells/mm3 was associated with a higher 
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MATERIALS AND METHODS
　　　
Study population and design
HIV-infected Koreans, who had continuously received cART 
comprising more than three antiretroviral drugs for at least 
six months with good clinical compliance to regular tri-
monthly visits at a university-affiliated tertiary care referral 
hospital (Seoul, Republic of Korea), were requested to par-
ticipate in the present study. We prospectively enrolled a to-
tal of 145 HIV-infected patients, excluding participants with 
a medication history of anti-platelet agents or statins that 
can affect cIMT level and plaque. The study protocol was 
approved by the Institutional Review Board of the Clinical 
Research Institute of Severance Hospital. Written informed 
consent was obtained from each participant.
Carotid IMT measurement
Carotid US was performed by a single specialist to deter-
mine the extent of subclinical carotid atherosclerosis. Scan-
ning of the extracranial common carotid artery, carotid bulb, 
and internal carotid artery in the neck was performed bilat-
erally from three different longitudinal and transverse pro-
jections.23 The average distance between the inner echogen-
ic line representing the luminal-intimal interface and the 
outer echogenic line representing the media-adventitia in-
terface was calculated by automatic IMT measurement 
software (Intimascope; Media Cross, Tokyo, Japan).23,24 The 
mean value of the bilateral average cIMT level was used as 
Mean-IMT in the analysis, and the greatest value among 
the measured cIMT levels was used as Max-IMT. For ca-
rotid US, a high-resolution real-time B-mode US with a 10-
MHz linear probe (LOGIQ 7; GE Medical Systems, Mil-
waukee, WI, USA) was used. Carotid plaque was defined 
as the presence of focal wall thickening that was at least 50% 
greater than that of the surrounding vessel wall, or as a focal 
region with a cIMT greater than 1.5 mm that protruded into 
the lumen and was distinct from the adjacent boundary.25
Body composition measurement and collection of 
laboratory and clinical data
Height, body weight, waist/hip circumference, and systolic 
and diastolic blood pressure (BP) were directly measured 
on the day of carotid US evaluation in all participants. Body 
mass index (BMI) and waist-hip ratio (WHR) were calcu-
lated. Blood samples were obtained after a 12 h overnight 
fast. Circulating levels of total cholesterol (T-C), low-densi-
risk of metabolic syndrome.5 In parallel, metabolic compli-
cations were frequently observed after a few years of 
cART initiation.6 Many morphologic and metabolic chang-
es correspond to metabolic syndrome criteria, according to 
the Adult Treatment Panel III (ATPIII) definition.7 These 
metabolic complications have been shown to be with an 
increased lifespan in HIV patients on cART, and naturally 
raise the question of whether HIV patients are at a higher 
risk for cardiovascular morbidity.8 Therefore, early detec-
tion of atherosclerosis may be necessary to prevent cardio-
vascular disease (CVD) in HIV-infected patients receiving 
cART.
Atherosclerosis is commonly observed in the carotid and 
coronary arteries.9 Measurement of carotid intima-media 
thickness (cIMT) and atherogenic plaque using ultrasound 
(US) is a noninvasive, sensitive and reproducible method 
for identifying and quantifying subclinical vascular athero-
sclerosis and for evaluating the risk of CVD.10 It is well 
known that cIMT level is a surrogate marker of atheroscle-
rosis,11 and is significantly associated with risks for myocar-
dial infarction, stroke and coronary heart disease in individ-
uals without symptomatic CVD.12,13 Carotid plaque has also 
been shown to be associated with cardiovascular events in 
healthy populations, with a prognostic power similar to or 
better than that of cIMT.14-16 In addition, pathological carot-
id US findings, including the existence of plaques and/or a 
cIMT level of more than 0.9 mm, exhibited a highly signifi-
cant direct association with all cardiovascular risk predic-
tors including estimated Framingham risk score in cART-
naïve HIV patients.17,18
Several previous studies have revealed that a decrease in 
estimated glomerular filtration rate (eGFR) is one risk fac-
tor for CVD19 and is correlated with cardiovascular mortali-
ty and morbidity in both high-risk groups20,21 and the gener-
al population.22
To the best of our knowledge, studies have yet to investi-
gate risk factors of carotid plaque and subclinical atheroscle-
rosis according to cIMT level in HIV-infected Asians receiv-
ing cART. In addition, there is little data on the clinical 
characteristics and associated factors of subclinical carotid 
atherosclerosis including eGFR among HIV-infected sub-
jects in the Asia-Pacific region. The objective of this study 
was to evaluate the risk factors of asymptomatic carotid 
plaque and the associations between cardiometabolic fac-
tors and carotid atherosclerosis as measured by cIMT in 
HIV-infected Asians and to discern whether eGFR level is 
associated with cIMT or the existence of plaque.
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evaluate the relationships between the value of cIMT or 
eGFR and other variables. The predictive power of cIMT to 
discriminate patients who had carotid plaque from those who 
did not was assessed by calculating the area under the receiv-
er operating characteristic (ROC) curve (AUC). The AUC 
ranged from 0.5 to 1.0, and the greater the AUC was, the bet-
ter the variables were. The optimal cutoff values of cIMT 
were selected to maximize the sum of the sensitivity and 
specificity derived from the ROC curves and the AUC analy-
sis (Youden index). All statistical analyses were performed 
using SPSS 12.0 software (SPSS Inc., Chicago, IL, USA).
RESULTS
 
Thirty-four (23.4%) of the 145 patients had carotid athero-
genic plaque. The mean age of the patients was 40.9±10.8 
years, and 139 patients were male. The mean duration of 
known HIV infection was 53.0±44.7 months, and the mean 
total duration of cART was 36.7±29.5 months. The mean 
values of CD4+ T lymphocyte count and log10[plasma HIV-
RNA VL] at the time of cIMT measurement were 349.1± 
176.2 cells/μL and 1.79±0.66 copies/mm3, respectively (Ta-
ble 1). 
Patients with carotid plaque were significantly older (49.0± 
10.4 yrs vs. 38.4±9.7 yrs, p<0.001) and had a higher preva-
lence of hypertension (38.7% vs. 7.3%, p<0.001), cerebro-
vascular attack (CVA) (12.9% vs. 0.0%, p=0.002), diabetes 
mellitus (12.9% vs. 1.8%, p=0.021) and metabolic syn-
drome (41.2% vs. 23.4%, p=0.043), compared to patients 
without plaque. WHR was significantly higher in patients 
with carotid plaque than in those without (0.88±0.05 vs. 
0.85±0.04, p=0.001) (Table 1).
Among the serum lipid profiles, glucose, and IR parame-
ters, T-C (181.6±36.7 mg/dL vs. 168.8±29.6 mg/dL, p= 
0.039), LDL-C (87.2±24.4 mg/dL vs. 74.9±25.3 mg/dL, 
p=0.033), glucose (106.9±25.6 mg/dL vs. 97.7±10.8 mg/dL, 
p=0.003), and fasting glucose-insulin ratio (13.09±13.87 vs. 
8.41±7.63, p=0.023) were significantly higher in patients 
with carotid plaque than in those without. In addition, the 
carotid plaque group had a higher cIMT level (Mean-IMT; 
0.68±0.17 mm vs. 0.56±0.09 mm, p<0.001 and Max-IMT; 
0.82±0.22 mm vs. 0.66±0.11 mm, p<0.001) and lower 
eGFR (90.58±19.14 mL/min per 1.73 m2 vs. 97.22±14.59 
mL/min per 1.73 m2, p=0.033) (Table 1). However, vari-
ables associated with HIV infection and cART were not 
significantly different between the groups (Table 2).
ty lipoprotein cholesterol (LDL-C), high-density lipopro-
tein cholesterol (HDL-C), triglyceride (TG), fasting insulin, 
and fasting glucose were analyzed using an enzymatic colo-
rimetric assay and lipoprotein electrophoresis (Hitachi, To-
kyo, Japan). Homeostasis model assessment of insulin resis-
tance as a marker for insulin resistance (IR) was calculated 
according to the following formula: [fasting glucose (mmol/
L)×fasting insulin (μIU/mL)/22.5].26 CD4+ T lymphocyte 
count was measured by flow cytometry (Beckman Coulter, 
Fullerton, CA, USA), and plasma HIV-RNA viral load 
(VL) was obtained by Roche diagnostics (COBAS AM-
PLICOR HIV-1 MONITOR, version 2.42; Roche, Basel, 
Switzerland) with a lower detection limit of 40 copies per 
milliliter. 
Kidney function was assessed through eGFR, which was 
calculated using the Modification of Diet in Renal Disease 
formula as follows27: 186.3×(serum creatinine-1.154)×(age-0.203) 
×(0.742 if female), with the serum creatinine concentration 
expressed as mg/dL. Clinical information including dura-
tion of known HIV infection and total duration of cART as 
well as all exposed antiretroviral drugs were collected. 
Based on the ATPIII criteria,7 metabolic syndrome was de-
fined as the presence of three or more or the following 
components: 1) waist circumference >88 cm in women or 
>102 cm in men; 2) systolic BP ≥130 mm Hg or diastolic 
≥85 mm Hg or use of antihypertensive medications; 3) TG 
≥150 mg/dL or use of lipid lowering medications (niacin, 
fenofibrate, and gemfibrozil); 4) fasting blood glucose ≥100 
mg/dL, physician diagnosed diabetes or use of diabetic medi-
cations; 5) HDL-C <50 mg/dL in women or <40 mg/dL in 
men. Hypertension was defined as the second component 
mentioned above.
Statistical analysis
All variables are expressed as the mean±standard deviation 
or number (percent), unless otherwise indicated. Statistical 
significance was set at p<0.05. Categorical variables were 
compared by χ2 analysis, and continuous variables with nor-
mal distributions were compared by Student’s t test. We an-
alyzed the continuous variables for normal distribution 
through the one-sample Kolmogorov-Smirnov test. Vari-
ables with p<0.05 in bivariate analysis were included in the 
logistic regression model for multivariate analysis to esti-
mate the odds ratio (OR) of the risk of carotid plaque, along 
with the 95% confidence interval (CI). Single linear univar-
iate correlations (Pearson’s correlation coefficients) and step-
wise multivariate regression analyses were performed to 
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(sensitivity=0.61 and specificity=0.76) (Fig. 1).
The levels of eGFR were inversely associated with Mean-
IMT (r=-0.379, p<0.001) and Max-IMT (r=-0.389, p<0.001). 
Correlations between cIMT and clinical and metabolic vari-
ables are shown in Table 4. Max-IMT and Mean-IMT had a 
significantly positive correlation with age (r=0.591, p<0.001, 
and r=0.589, p<0.001, respectively), BMI (r=0.189, p<0.024, 
and r=0.168, p<0.044 respectively), WHR (r=0.372, p<0.001, 
and r=0.353, p<0.001, respectively), T-C (r=0.282, p=0.001, 
and r=0.242, p=0.003, respectively), LDL-C (r=0.258, p= 
0.006, and r=0.208, p=0.026, respectively), and fasting glu-
cose (r=0.292, p<0.001, and  r=0.294, p<0.001). In addition, 
the total duration of cART was significantly positively asso-
In the multivariate logistic regression model to identify 
risk factors for carotid artery plaque in HIV-infected pa-
tients receiving cART, older age (older than 40 years, OR 
6.16, 95% CI 1.09-34.88, p=0.040), hypertension (OR 12.62, 
95% CI 1.72-92.49, p=0.013), and higher LDL-C level (OR 
1.08, 95% CI 1.01-1.16, p=0.039) were identified (Table 3).
The ability of Mean-IMT and Max-IMT to predict carotid 
artery plaque was further examined by ROC curve analyses. 
The AUCs for Mean-IMT and Max-IMT were 0.74 (95% CI 
0.65-0.84, p<0.001) and 0.76 (95% CI 0.67-0.85, p<0.001), 
respectively. The cut-off level for the greatest sensitivity and 
specificity for Mean-IMT was 0.62 mm (sensitivity=0.59 
and specificity=0.82), and that for Max-IMT was 0.71 mm 
Table 1. Characteristics of all Patients and Comparison of Clinical and Laboratory Parameters between the Carotid Plaque 
and Non-Plaque Group
Variable Total (n=145)
Common carotid artery
p valuePlaque (-) 
n=111 (76.6%)
Plaque (+)
n=34 (23.4%)
Age, yrs   40.9±10.8 38.4±9.7   49.0±10.4 <0.001
    ≥40 yrs   74 (51.0)   46 (41.4) 28 (82.4) <0.001
Male 139 (95.9) 106 (95.5) 33 (97.1) 1.000
Medical history
    Hypertension   20 (14.2)   8 (7.3) 12 (38.7) <0.001*
    CVA   4 (2.8)   0 (0.0)   4 (12.9)   0.002*
    DM   6 (4.3)   2 (1.8)   4 (12.9)   0.021*
Metabolic syndrome, yes   40 (27.6)   26 (23.4) 14 (41.2) 0.043
Body composition parameter
    WHR   0.86±0.05   0.85±0.04   0.88±0.05 0.001
    BMI (kg/m2) 23.2±2.9 23.0±2.8 23.9±3.2 0.148
Systolic BP (mm Hg) 129.5±14.3 129.1±13.4 130.9±17.0 0.532
Diastolic BP (mm Hg)   78.2±10.9   77.7±11.4 79.6±8.9 0.383
T-C (mg/dL) 171.8±31.7 168.8±29.6 181.6±36.7 0.039
LDL-C (mg/dL)   77.6±25.5   74.9±25.3   87.2±24.4 0.033
HDL-C (mg/dL)   48.1±12.4   48.9±12.9 45.3±9.8 0.157
TG (mg/dL)   253.9±161.7   246.8±155.3   277.7±182.3 0.352
Glucose (mg/dL)   99.9±15.9   97.7±10.8 106.9±25.6 0.003
Log[HOMA-IR]   1.30±1.02   1.38±1.00   1.04±1.06 0.118
Fasting insulin (μIU/mL)   24.4±29.5   26.2±32.2    18.6±17.7 0.228
Fasting GI ratio   9.55±9.68   8.41±7.63   13.09±13.87 0.023
Carotid IMT (mm)
    Mean-IMT   0.59±0.13   0.56±0.09   0.68±0.17 <0.001
    Max-IMT   0.70±0.16   0.66±0.11   0.82±0.22 <0.001
Smoking (pack-yrs)    9.7±10.2   9.2±9.9   11.8±10.8 0.214
Past or current smoker   97 (69.8)   75 (68.8) 22 (73.3) 0.633
eGFR (mL/min per 1.73 m2)   95.66±15.95   97.22±14.59   90.58±19.14 0.033
BMI, body mass index; BP, blood pressure; CVA, cerebro-vascular accident; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; GI ratio, 
glucose-insulin ratio; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; IMT, intima-media thick-
ness; LDL-C, low-density lipoprotein cholesterol; T-C, total cholesterol; TG, triglycerides; WHR, waist-hip-ratio. 
Data are expressed as mean±standard deviation or number (percent).
*Fisher’s Exact Test. 
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tively), and fasting glucose (p=0.012 and p=0.009, respec-
tively) remained significant clinical factors independently 
associated with Max-IMT and Mean-IMT (adjusted R2=0.384 
and 0.345, respectively) (Table 4).
DISCUSSION
The present study revealed that older age (≥40 years), hy-
pertension and higher LDL-C level are the independent clin-
ical factors associated with the existence of carotid plaque in 
HIV-infected Koreans receiving cART. In addition, we con-
firmed that Max-IMT and Mean-IMT are significantly as-
sociated with the existence of carotid plaque and found that 
cIMT is correlated with traditional CVD risk factors in 
HIV-infected Koreans.
According to our multivariate analysis, the presence of 
documented hypertension and a 1 mg/dL increase in LDL-
C were associated with 12.62 and 1.08 times higher risk of 
carotid plaque, respectively. In addition, older patients with 
HIV demonstrated a greater incidence of carotid plaque (es-
pecially those over 40). It is generally well accepted that 
hypertension and dyslipidemia promote atherosclerosis and 
ciated with Max-IMT and Mean-IMT (r=0.175, p=0.036, and 
r=0.177, p=0.034, respectively) in univariate analysis. In 
the multiple stepwise regression analyses, age (p<0.001 and 
p<0.001, respectively), T-C (p=0.003 and p=0.031, respec-
Table 2. Comparison of Variables of HIV Infection and cART between the Carotid Plaque and Non-Plaque Group
Variable Total (n=145)
Common carotid artery
p valuePlaque (-)
n=111 
Plaque (+)
n=34 
Known duration of HIV infection (month) 53.0±44.7 50.8±44.9 60.2±43.7 0.285
CD4+ T lymphocyte count (/μL) 349.1±176.2 354.1±174.6 332.9±183.3 0.540
Log10[HIV-RNA] (copies/mm3) 1.79±0.66 1.82±0.70 1.75±0.54 0.603
Total duration of cART (months) 36.7±29.5 35.2±29.1 41.8±30.8 0.256
PIs* 82 (56.6) 61 (55.0) 21 (61.8) 0.483
NNRTIs* 71 (49.0) 52 (46.8) 19 (55.9) 0.356
NRTI*
    Stavudine 41 (28.3) 27 (24.3) 14 (41.2) 0.056
    Didanosine 63 (43.4) 47 (42.3) 16 (47.1) 0.627
    Zidovudine 99 (68.3) 79 (71.2) 20 (58.8) 0.176
cART, combined antiretroviral therapy; NNRTI, nonnucleoside analogue reverse transcriptase inhibitor; NRTI, nucleoside analogue reverse transcriptase 
inhibitor; PI, protease inhibitor; US, using ultrasound.
Data are expressed as mean±standard deviation or number (percent).
*These variables indicate continuous exposure history of PIs or NNRTIs or NRTI for more than six months before carotid US measurement.
Table 3. Multivariate Logistic Regression Model to Identify Clinical Factors Indicating the Existence of Carotid Artery Plaque 
in HIV-Infected Patients Receiving cART
Variable OR 95% CI p value
Old age (≥40 yrs old)   6.16   1.09-34.88 0.040
Hypertension 12.62   1.72-92.49 0.013
LDL-C (mg/dL)   1.08 1.01-1.16 0.039
cART, combined antiretroviral therapy; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; CI, confidence interval.
Fig. 1. ROC curves for Max-IMT and Mean-IMT for the prediction of carotid 
artery plaque. The area under the ROC curves for Mean-IMT and Max-IMT 
were 0.74 (95% CI 0.65-0.84, p<0.001) and 0.76 (95% CI 0.67-0.85, p<0.001), 
respectively. CI, confidence interval; IMT, intima-media thickness; ROC, re-
ceiver operating characteristic.
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Although the wide performance of cART has prolonged 
the life expectancy of individuals infected with HIV,35 the 
accelerated onset of CVD has emerged as a concerning 
complication of chronic HIV infection and long-term use of 
cART.36 Moreover, there is increasing evidence supporting 
the initiation of cART in asymptomatic HIV-infected pa-
tients and a CD4+ T lymphocyte count >500 cells/mm3.37 It 
is, therefore, increasingly more relevant to stratify patients 
for CVD risk when cART is being initiated or when treat-
ment regimens are being adjusted.38 Arterial stiffness, a 
marker of CVD and an independent predictor of its corre-
sponding risk, is associated with impaired endothelial func-
tion.39 HIV may affect the vasculature directly via endotheli-
al damage,40 and the virus-mediated inhibition of cholesterol 
efflux from macrophages with consequent reduced HDL-C 
levels,41 which promotes arterial stiffness and contributes to 
atherogenesis.42 Furthermore, HIV treatment, especially 
protease inhibitors may accelerate atherosclerosis especial-
ly due to metabolic side effects including dyslipidemia and 
IR.43,44 However, we found that subclinical carotid athero-
sclerosis was not associated with duration of HIV infection 
or cART regimen. Any association of HIV with atheroscle-
consequently increase IMT in non-HIV-infected individu-
als.28 Prospective studies of large populations have reported 
a correlation between circulating concentration of total cho-
lesterol and LDL-C with IMT in both non-HIV-infected 
Caucasian28 and Eskimos.29 Also, older age is known to be 
a major risk factor for the development of CVD.30 Endothe-
lium-dependent dilation of vessels becomes impaired with 
age,31,32 and is thought to contribute to the age-associated 
increase in CVD risk.30 In our study, we observed similar 
associations between hypertension, LDL-C, age and carotid 
plaque in HIV-infected patients receiving cART. 
The results of our study reveal that the presence of sub-
clinical carotid plaque is a frequent occurrence among HIV-
infected patient receiving cART (23.4%). Our present ob-
servation, however, could be limited by the absence of age-
matched HIV non-infected controls. Nevertheless, this high 
prevalence is in line with other previous observations,33,34 
and only 6.7% of subclinical carotid lesions have been ob-
served in an age-matched control group of 104 HIV-nega-
tive subjects. Furthermore, 20.9% of subclinical carotid le-
sions have been reported in HIV-infected patients naïve to 
cART.18
Table 4. Correlations between Max-IMT/Mean-IMT and Clinical and Metabolic Variables
Variable
Max-IMT (mm)
Univariate* Multivariate† Univariate* Multivariate†
r p value β F p value r p value β F p value
Age (yrs) 0.591 <0.001 0.434 29.03 <0.001 0.589 <0.001 0.421 25.69 <0.001
BMI (kg/m2) 0.189 0.024 0.168 0.044
WHR 0.372 0.001 0.353 <0.001
Systolic BP (mm Hg) -0.013 0.885 -0.036 0.675
Diastolic BP (mm Hg) 0.056 0.520 0.048 0.584
T-C (mg/dL) 0.282 0.001 0.232 9.27   0.003 0.242 0.003 0.171   4.76   0.031
LDL-C (mg/dL) 0.258 0.006 0.208 0.026
HDL-C (mg/dL) -0.061 0.488 -0.052 0.550
TG (mg/dL) 0.072 0.406 0.080 0.358
Fasting glucose (mg/dL) 0.292 <0.001 0.207 6.46   0.012 0.294 <0.001 0.223   7.05   0.009
Log[smoking] (pack-yr) 0.143 0.171 0.150 0.150
eGFR (mL/min per 1.73 m2) -0.389 <0.001 -0.379 <0.001
Total duration of cART (months) 0.175 0.036 0.177 0.034
CD4+ T lymphocyte count (/μL) 0.024 0.771 0.017 0.838
Log10[HIV-RNA] (copies/mm3) -0.012 0.890 -0.001 0.996
R2 0.401 0.363
Adjusted R2 0.384 0.345
BMI, body mass index; BP, blood pressure; cART, combined active antiretroviral therapy; eGFR, estimated glomerular filtration rate; HDL-C, high-density 
lipoprotein cholesterol; IMT, intima-media thickness; LDL-C, low-density lipoprotein cholesterol; T-C, total cholesterol; TG, triglycerides; WHR, waist-hip-
ratio.
β indicates regression coefficients. 
*Univariate coefficients. 
†Stepwise multivariate regression analysis.
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tive control group for comparison. 
In spite of these limitations, this study has clinical signifi-
cance since it is the first report to evaluate the relationships 
between carotid atherosclerosis and metabolic risk factors 
in Asian patients with HIV. In conclusion, we demonstrated 
that the presence of hypertension, high LDL-C and old age 
are independent clinical factors of carotid plaque among 
HIV-infected Koreans. Future studies on the process of ath-
erosclerosis in HIV-infected patients receiving cART are 
needed, including direct comparison between multiethnic 
HIV-infected patients and non-HIV-infected subjects.
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